Nociceptinergic system as potential target in Parkinson's disease

Kornelia Tekes, Saeed Tariq, Ernest Adeghate, Rudolf Laufer, Farzad Hashemi, Afshan Siddiq, Huba Kalasz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Nociceptinergic system has become an important target for drug development since the identification of the "orphan", opioid-like-1 receptor and the isolation of its endogenous agonist nociceptin. Involvement of nociceptinergic system has been verified in a wide range of pathophysiological processes. A large number of nociceptinergic agonists and antagonists with peptide and non-peptide structures have been developed. Several non-peptide nociceptinergic antagonists have recently shown effective on different animal models of parkinsonism. Neuropharmacological background for antiparkinsonian effect of nociceptinergic antagonists, experimental models with high predictive value, nociceptinergic antagonists shown to have potential effect in Parkinson's disease are summarized. Medicinal chemistry data (logP and TPSA) of the NOP receptor antagonists which are found to be effective in animal models of Parkinson's disease are provided.

Original languageEnglish
Pages (from-to)1389-1397
Number of pages9
JournalMini-Reviews in Medicinal Chemistry
Volume13
Issue number10
DOIs
Publication statusPublished - Aug 20 2013

Keywords

  • Animal models of parkinson's disease
  • Antiparkinsonian effect
  • LogP
  • Medicinal chemistry data
  • Nop receptor antagonists
  • TPSA

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Fingerprint Dive into the research topics of 'Nociceptinergic system as potential target in Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this